Enveda Announces Phase 1 Trial Results for ENV-308 Exercise Pill
Boulder biotech Enveda announced Phase 1 clinical trial results for ENV-308, an experimental oral drug designed to mimic the weight management and metabolic effects of exercise. Tested on 88 healthy adults, the once-daily pill demonstrated safety, good tolerability, and a favorable gastrointestinal profile, positioning it as a distinct alternative or complement to GLP-1 medications. Scientists … Read more